Table 4.

Medications at time of development of pulmonary symptoms^*

Medication	Number of patients	Mean exposure in months ± SD (range)
Corticosteroids	24	47.3 ± 48.2 (3–161)
Cyclosporine	7	6.3 ± 7.3 (1–22)
Etoposide	1	1
Gold	1	53
Methotrexate	13	32.9 ± 38.2 (1–126)
Thalidomide	1	22
IL1 inhibitor (any)	12	15.1 ± 15.0 (3–47)
Anakinra	10	16.9 ± 15.9 (3–47)
Canakinumab	1	6
Rilonacept	1	6
TNF inhibitor (any)	3	17.0 ± 13.1 (2–26)
Adalimumab	2	12.5 ± 14.9 (2–23)
Etanercept	1	26
Tocilizumab	2	6.0 ± 7.1 (1–11)

^*Or discontinued within a month prior to symptoms

SD = standard deviation